Dr. Christina Kunz

Dr. Christina Kunz

Dr. Christina Kunz

Position:

Scientist

Phone:

+49 6221 42 2260

Fax:

+49 6221 42 2397

Building:

TP 4

Room:

S4.223

Area of Work

Analysis of prospective and retrospective studies, survival analysis, clinical trials, trial statistician of the German-Speaking Myeloma Multicenter Group (GMMG)

 

Special Interests

Flexible designs in clinical survival trials, biomarker-guided trial concepts                              

 

  

Selected Publications

  1. Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO (2015). Translocation t(11;14) is associated with adverse outcome in newly diagnosed AL amyloidosis patients when treated with bortezomib based regimen. Journal of Clinical Oncology 33(12) 1371-1378.
  2. Merz M, Ritsch J, Kunz C, Wagner B, Sauer S, Hose D, Moehler T, Delorme S, Goldschmidt H, Zechmann C, Hillengass J (2015). Dynamic contrast-enhanced magnetic resonance imaging for assessment of anti-angiogenic treatment effects in multiple myeloma. Clinical Cancer Research 21(1) 106-112.
  3. Kunz C, Kieser M (2014). Blinded versus Unblinded Covariate Selection in Confirmatory Survival Trials. J Biopharm Stat 24(2) 398-414.
  4. Bochtler T, Stölzel F, Heilig C, Kunz C, Mohr B, Jauch A, Janssen JWG, Kramer M, Benner A , Bornhäuser M, Ho AD, Ehninger G, Schaich M, Krämer A (2013). Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukaemia. Journal of Clinical Oncology 31: 3898-3905.
  5. Wunder C [Kunz C], Kopp-Schneider A, Edler L (2012). An adaptive group sequential phase II design to compare treatments for survival endpoints in rare patient entities. J Biopharm Stat. 22(2) 294-311.
  6. Wittmann S, Wunder C [Kunz C], Zirn B, Furtwängler R, Wegert J, Graf N, Gessler M (2008). New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Genes Chromosomes Cancer 47(5) 386-395.

to top